Ulocuplumab (Anti-CXCR4 / CD184)

Synonyms: BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody

Catalog No.A2523 Purity:99%

Ulocuplumab (Anti-CXCR4 / CD184) is a fully human IgG4 antibody, targeting CXCR4. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. MW: 144.84 KD.

Purity & Quality Control

Batch: A252301 Purity: 99% Protein concentration: 6.72mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective CXCR Inhibitors

Name	Citation	CXCR1	CXCR2	CXCR4	CXCR3	Others
WZ811	20			++++
Mavorixafor	0			+
AMG 487	1				+++
Motixafortide (BL-8040)	0			++++		cyclin-D1,MCL-1,Bcl-2
Navarixin (SCH-527123)	6	++	+++
MSX-122	1			+++
LY2510924	2			++++
Reparixin (Repertaxin)	18	++++	+			CXCL8
SB225002	78		++
SB 265610		✔
Balixafortide (POL6326)			✔
SX-682	✔
MSX-130			✔
MSX-127			✔
AZD5069		✔
Danirixin (GSK1325756)		✔			CXCL8
LIT-927			✔		CXCL12
AMD3465 hexahydrobromide			✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Ulocuplumab (Anti-CXCR4 / CD184) is a fully human IgG4 antibody, targeting CXCR4. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. MW: 144.84 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1375830-34-4
Molecular Weight	144.84 kDa
Isotype	Human IgG4SP
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.

Tags: buy Ulocuplumab (Anti-CXCR4 / CD184) | Ulocuplumab (Anti-CXCR4 / CD184) supplier | purchase Ulocuplumab (Anti-CXCR4 / CD184) | Ulocuplumab (Anti-CXCR4 / CD184) cost | Ulocuplumab (Anti-CXCR4 / CD184) manufacturer | order Ulocuplumab (Anti-CXCR4 / CD184) | Ulocuplumab (Anti-CXCR4 / CD184) distributor